Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: An origin independent of DNA damage?

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 21-28

  Merle, Patrick ^a   Morvan, Daniel ^b,c,d   Caillaud, Denis ^a,d   Demidem, Aicha ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b INSERM   (France)

^c Centre Regional de Lutte Contre le Cancer Jean Perrin   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Bystander effect; Chloroethylnitrosoureas; Melanoma; Murine type; NMR spectroscopy

Indexed keywords

CARMUSTINE; CHLOROETHYLNITROSOUREA DERIVATIVE; CYSTEMUSTINE; FOTEMUSTINE; GLUTATHIONE; PHOSPHOLIPID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG STRUCTURE; HISTOPATHOLOGY; MALE; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; DNA DAMAGE; GLUTATHIONE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, SECOND PRIMARY; NITROSOUREA COMPOUNDS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHOLIPIDS; VINYL CHLORIDE;

EID: 40549127132     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Boyle P, Maisonneuve P and Dore JF: Epidemiology of malignant melanoma. Br Med Bull 51: 523-547, 1995.
2. Menegoz F, Black RJ, Arveux P, Magne V, Ferlay J, Buemi A, Carli PM, Chapelain G, Faivre J, Gignoux M, Grosclaude P, Mace-Lesec'h J, Raverdy N and Schaffer P: Cancer incidence and mortality in France 1975-95. Eur J Canc Prev 6: 442-466, 1997.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA and Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16): 3635-3648, 2001.
4. Negrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, Dorval T, Garbay JR and Vilmer C: Standards, Options and recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Federation Nationale des Centres de Lutte Contre le Cancer. Bull Cancer 87: 173-182, 2000.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hopper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949- 954, 2002.
6. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB and Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257-264, 2007.
7. Abbott KL and Harman GS: Combination chemotherapy for disseminated malignant melanoma. Anticancer Drugs 6: 489-497, 1995.
8. Dummer R, Gore ME, Hancock BW, Guillou PJ, Grobben HC, Becker JC, Oskam R, Dieleman JP and Burg G: A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer 75: 905-907, 1995.
9. Demidem A, Morvan D, Papon J, De Latour M and Madelmont JC: Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res 61: 2294-2300, 2001.
10. Morvan D, Demidem A, Papon J, De Latour M and Madelmont JC: Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy on intact tumor samples. Cancer Res 62: 1890-1897, 2002.
11. Demidem A, Morvan D and Madelmont JC: Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells a relay for chemotherapy? Int J Cancer 119: 992-1004, 2006.
12. Merle P, Morvan D, Madelmont JC, Caillaud D and Demidem A: CENU treatment induced bystander effects which are effective on parental and non-parental tumors and have a phospholipid metabolism proton NMR spectroscopy signature. Int J Oncol 29: 637-642, 2006.
13. Madelmont JC, Godeneche D, Parry D, Duprat J, Chabart JL, Plagne R, Mathe G and Meyniel G: Cystemustine. Drug Future 19: 27-30, 1994.
14. Droz JP, Cvitkovic E, Armand JP and Khoury S: Handbook of chemotherapy in clinical oncology. F.I.I.S., pp. 166-167, 1988.
15. 6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368-5372, 1990.
16. Cook MG, Clarke TJ and Hamphreys S: The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC melanoma. Histopathology 28: 497-512, 1996.
17. Morvan D, Demidem A, Papon J and Madelmont JC: Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl-nitrourea: demonstration of phospholipid metabolism alterations. Magn Reson Med 49: 241-248, 2003.
18. 13C nuclear magnetic resonance spectroscopy. Magn Reson Med 55: 984-996, 2006.
19. Kwiatkowski F, Girard M, Hacene K and Berlie J: Sem: a suitable statistical software adaptated for research in oncology. Bull Cancer 87: 715-721, 2000.
20. Slater LM, Stupecky M, Sweet P, Osann K, Eklof A and Arquilla ER: Etoposide induction of tumor immunity in Lewis lung cancer. Cancer Chemother Pharmocol 48: 327-332, 2001.
21. Yin JH, Yang DI, Chou H, Thompson EM, Xu J and Hsu CY: Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1- nitrosourea in C6 glioma cells. J Pharmacol Exp Ther 297: 308-315, 2001.
22. Morvan D and Demidem A: Metabolomics by proton NMR spectroscopy of the response to chloroethyl-nitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 67: 2150-2159, 2007.